Compare Bristol-Myers Squibb Co (BMY) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Sprott Uranium Miners ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.98 (market cap $129.94B), while Sprott Uranium Miners ETF trades at $55.47. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while Sprott Uranium Miners ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals.
| BMY | URNM | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $65.89 | $83.99 |
52-Week Low | $42.60 | $44.14 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
URNM trades at $55.50, up 1.65% today, with a bullish technical signal driven by moving averages. Recent news highlights strong nuclear sector tailwinds from AI power demand and government funding, though some articles question miner valuations. Support and resistance cluster tightly around $55-56, indicating potential volatility.
The outlook is positive given nuclear energy's role in AI infrastructure, but risks include uranium price volatility and concentrated miner exposure. Analyst sentiment is mixed, with debates over supply chain positioning versus pure uranium price leverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
